XELOX方案与FOLFOX方案治疗101例晚期大肠癌的临床观察

目的:比较奥沙利铂联合卡培他滨(XELOX方案)与奥沙利铂联合氟尿嘧啶+亚叶酸钙(FOLFOX方案)治疗晚期大肠癌近期疗效和不良反应。方法:101例晚期大肠癌患者随机分成XELOX组54例和FOLFOX组47例进行化疗。XELOX方案:奥沙利铂130 mg.m-2,静脉滴注,d1;卡培他滨2 500 mg.m-2.d-1,分早晚2次口服,d1～14。FOLFOX:奥沙利铂130 mg.m-2,静脉滴注,d1;氟尿嘧啶400 mg.m-2,静脉注射,d1;氟尿嘧啶2.4～3 g.m-2,静脉持续输注46 h,d1,2;亚叶酸钙200 mg.m-2,静脉滴注,d1。每3周重复。结果:XELOX方案总有效率(CR+PR)为46.30%,中位疾病进展时间7.8个月,中位生存期13.5个月。FOLFOX方案总有效率(CR+PR)为42.6%,中位疾病进展时间6.5个月,中位生存期11.8个月。2组疗效比较,差异无统计学意义(P>0.05)。结论:2种方案治疗晚期大肠癌有效率近似,不良反应均可耐受,但XELOX方案的耐受性、患者依从性更好。

XELOX Regimen vs. FOLFOX Regimen for Advanced Colon Carcinoma: Clinical Observation of 101 Cases

OBJECTIVE： To evaluate the short-term efficacy and adverse reactions of oxaliplatin combined capecitabine（XELOX regimen） vs.oxaliplatin plus fluorouracil and calcium folinate（FOLFOX regimen） in the treatment of advanced colon cancer.METHODS： 101 patients with advanced colon cancer were randomly assigned to receive oxaliplatin（130 mg·m-2 iv gtt on day 1） plus capecitabine（2 500 mg·m-2.d-1 orally every morning and every evening on day 1 through 14 days）（XELOX group,n = 54） or oxaliplatin（130 mg·m-2 iv gtt on day 1） plus fluorouracil（400 mg·m-2,iv gtt on day 1）,fluorouracil（2.4 ～ 3 g·m-2,continuous infusion for 46 hours on 1 and 2 days） and calcium folinate（200 mg·m-2 iv gtt on day 1）（FOLFOX group,n = 47）.The treatment cycle was repeated in every 3 weeks.RESULTS： The patients receiving XELOX showed an overall response rate（CR ＋ PR） of 46.30%,median time to progression of 7.8 months and median survival of 13.5 months,as compared with an overall response rate（CR ＋ PR） of 42.6%,median time to progression of 6.5 months and median survival of 11.8 months in patients receiving FOLFOX,showing no significant differences between the two groups（P 〉 0.05）.CONCLUSION： Both XELOX regimen and FOLFOX regimen had similar efficacy and tolerable adverse reactions in the treatment of advanced colon cancer,but the patients in XELOX group showed better tolerance and better compliance.